2020
Peter McCullough said that when the COVID vaccine campaign began on December 10, 2020, previously infected and pregnant people who had been excluded from trials were encouraged to take it.
“December 10th, 2020, when it rolls out, they said, Well, damn, the torpedoes, everybody takes it.”
Peter McCullough · #2576 - Dr. Peter McCullough, 0:47:06
2021
Neeley says Moderna had only about 800 employees early in the COVID period while Pfizer had 100,000, and Moderna's CEO calls it a technology company that happens to do biology.
“technology company that happens to do biology. And what we know from Moderna early early on during the COVID days they had only 800 employees Pfizer had 100,000 employees”
Guest · Strategy Summit 2026: Why AI Means Radical Change, 0:12:51
2025
Peter McCullough said the McCullough Foundation estimated, from Pfizer and Moderna sales data, that 8.9% of people took a COVID booster in the previous year.
“it was 8.9% of people took a booster last year”
Peter McCullough · #2576 - Dr. Peter McCullough, 1:44:59
Undated
Veeva Systems' first multimillion-dollar annual deals came from the pharmaceutical company Pfizer, according to Peter Gassner.
“the first multimillion dollar annual deals were a big customer, Pfizer.”
Acquired · Capital-Efficient Growth (with Zoom CEO Eric Yuan & Veeva CEO Peter Gassner), 0:26:55
Undated
Salesforce.com told Veeva Systems during the Pfizer competition that Veeva would never win the deal, but Veeva won it, according to Peter Gassner.
“There was a partner at the time, actually, Salesforce.com actually at the time said, oh, you know, send a note that Veeva will never win this deal.”
Acquired · Capital-Efficient Growth (with Zoom CEO Eric Yuan & Veeva CEO Peter Gassner), 0:26:55
Undated
Peter Gassner said Veeva Systems used the Pfizer invoice to fund product development, which he compared to a $3 million round without dilution.
“I thought, oh, we've just raised a $3 million round of capital here. It didn't cost us any dilution, right?”
Acquired · Capital-Efficient Growth (with Zoom CEO Eric Yuan & Veeva CEO Peter Gassner), 0:28:12
Undated
Walmsley said GSK's consumer division was built through two global joint ventures, first with Novartis's portfolio and then with Pfizer's.
“we went through two massive global joint ventures, firstly with Novartis's portfolio and integrations, frankly, uh, and then with Pfizer's.”
Emma Walmsley · GSK CEO: Drug Discovery, AI in Pharma, and Changing Company Culture, 0:32:23